Document Type: Original Research


1 Cancer Research Center, Babol University of Medical Sciences, Babol, Iran

2 Department of Pathology, Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Radio-Oncology, Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

4 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran


Background & Objective: Prediction of response to neoadjuvant treatment is an important part of treatment of patients with breast cancer. This study aimed to assess changes in serum levels of Cytokeratin 18 during neoadjuvant chemotherapy in patients with locally advanced breast cancer and its association with neoadjuvant treatments.
Methods: This research was performed on newly diagnosed breast cancer patients referred to Omid Radiotherapy Center and radiotherapy and oncology departments of Emam Reza and Ghaem hospitals, in Mashhad, Iran. Serum levels of M30 and M65 fragments of Cytokeratin 18 were measured before and 24 hours after the first course of neoadjuvant chemotherapy. Changes in serum levels of Cytokeratin 18 and its fragments and their correlation with pathologic response were analyzed.
Results: Pre- and post-chemotherapy levels of M30 were respectively 223.9±18.94 and 250.7±23.92 U/L (P=0.24). For M65, these levels were respectively 301.5±313.9 and 330.2±352.2 U/L (P=0.1). Changes in M30 level during chemotherapy in patients with and without pathologic complete response were -20±92.69 and 43.1±106.5, respectively (P=0.1). For M65, these changes were respectively -247±55 and 76±240 (P=0.1). Baseline levels of M30 and M65 had no relation with menopausal status, tumor grade, hormone receptor status, Ki67 expression, molecular subtype, and stage. 
Conclusion: Our findings showed statistically insignificant changes in the level of Caspase-cleaved- (M30) and uncleaved- (M65) cytokeratin 18 fragments (apoptotic and necrotic indicators, respectively) during neoadjuvant chemotherapy in patients with breast cancer. There was no notable relationship between tumor-related factors and either baseline levels or serum changes of CK18 fragments. Also, there was no correlation between M30/M65 level and pathologic response to neoadjuvant chemotherapy.


Main Subjects

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90. [DOI:10.3322/caac.20107] [PMID]
  2. Salek R, Shahidsales S, Mozafari V. Changing pattern in the clinical presentation of breast cancer in the absence of a screening program over a period of thirty-three years in Iran. The Breast. 2016;28:95-9. [DOI:10.1016/j.breast.2016.05.003] [PMID]
  3. Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol. 2001;28:389-99. [DOI:10.1053/sonc.2001.26150]
  4. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Annals of Oncology. 2018;29(8):1634-57. [DOI:10.1093/annonc/mdy192] [PMID]
  5. Teshome M, Hunt KK. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014;23(3):505-23. [DOI:10.1016/j.soc.2014.03.006] [PMID] [PMCID]
  6. Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508-16. [DOI:10.1245/s10434-011-2108-2] [PMID]
  7. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Annals of surgical oncology. 2006;13(11):1443-9. [DOI:10.1245/s10434-006-9086-9] [PMID]
  8. Rauch GM, Adrada BE, Kuerer HM, van la Parra RFD, Leung JWT, Yang WT. Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal of Roentgenology. 2017;208(2):290-9. doi:10.2214/AJR.16.17223. [DOI:10.2214/AJR.16.17223] [PMID]
  9. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer investigation. 2006;24(7):669-76. [DOI:10.1080/07357900600981307] [PMID]
  10. Fehm T, Becker S, Becker-Pergola G, Sotlar K, Gebauer G, Durr-Storzer S, et al. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res. 2006;8(5):R60. [DOI:10.1186/bcr1611] [PMID] [PMCID]
  11. Oshima RG, Baribault H, Caulin C. Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev. 1996;15(4):445-71. [DOI:10.1007/BF00054012] [PMID]
  12. Stoetzer OJ, Fersching DMI, Salat C, Steinkohl O, Gabka CJ, Hamann U, et al. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin. Cancer Letters. 2013;336(1):140-8. [DOI:10.1016/j.canlet.2013.04.013] [PMID]
  13. Tas F, Karabulut S, Yildiz I, Duranyildiz D. Clinical significance of serum M30 and M65 levels in patients with breast cancer. Biomedicine & Pharmacotherapy. 2014;68(8):1135-40. [DOI:10.1016/j.biopha.2014.10.021] [PMID]
  14. Javadinia SA, Shahidsales S, Fanipakdel A, Mostafapour A, Joudi‐Mashhad M, Ferns GA, et al. The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy. Current Pharmaceutical Design. 2018;24(39):4646-51. [DOI:10.2174/1381612825666190110143258] [PMID]
  15. Javadinia SA, Shahidsales S, Fanipakdel A, Joudi‐Mashhad M, Mehramiz M, Talebian S, et al. Therapeutic potential of targeting the Wnt/β‐catenin pathway in the treatment of pancreatic cancer. Journal of Cellular Biochemistry. 2019;120(5):6833-40. [DOI:10.1002/jcb.27835] [PMID]
  16. Fanipakdel A, Seilanian Toussi M, Rezazadeh F, Mohamadian Roshan N, Javadinia SA. Overexpression of cancer-testis antigen melanoma-associated antigen A1 in lung cancer: A novel biomarker for prognosis, and a possible target for immunotherapy. Journal of Cellular Physiology. 2019;234(7):12080-6. [DOI:10.1002/jcp.27884] [PMID]
  17. Fanipakdel A, Javadinia S, Memar B, Homayundust S. P-008 Plasma cytokeratin-18 level of patients with esophagogastric cancer as a biomarker of tumour response. Annals of Oncology. 2019;30(Supplement_4):mdz155. 007. [DOI:10.1093/annonc/mdz155.007] [PMID]
  18. Turk HM, Aliyev A, Celik RS, Seker M, Coban E, Demir T, et al. Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer. Current Problems in Cancer. 2020;44(1):100497. [DOI:10.1016/j.currproblcancer.2019.06.009] [PMID]
  19. Abdelrahman AE, Rashed HE, Abdelgawad M, Abdelhamid MI. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer. Annals of Diagnostic Pathology. 2017;28:43-53. [DOI:10.1016/j.anndiagpath.2017.01.009] [PMID]
  20. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clinical Cancer Research. 2007;13(11):3198-206. [DOI:10.1158/1078-0432.CCR-07-0009] [PMID]
  21. Gemechu Y, Seifu D, Tigneh W, Labisso WL. Caspase-Cleaved Cytokeratin 18 as a Potential Molecular Biomarker for Monitoring Chemotherapeutic Response in Breast Cancer Patients. J Mol Genet Med 2018;12(39). [DOI:10.4172/1747-0862.1000339]
  22. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer. 2007;56(3):399-404. [DOI:10.1016/j.lungcan.2007.01.015] [PMID]
  23. Krawczyk N, Hartkopf A, Banys M, Meier-Stiegen F, Staebler A, Wallwiener M, et al. Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients. BMC Cancer. 2014;14:394. [DOI:10.1186/1471-2407-14-394] [PMID] [PMCID]
  24. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res. 1996;2(11):1879-85.
  25. Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. Down-Regulated Expression of Cytokeratin 18 Promotes Progression of Human Breast Cancer. Clinical Cancer Research. 2004;10(8):2670-4. [DOI:10.1158/1078-0432.CCR-03-0114] [PMID]